Compare STRO & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | ICCC |
|---|---|---|
| Founded | 2003 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.9M | 55.5M |
| IPO Year | 2018 | 1987 |
| Metric | STRO | ICCC |
|---|---|---|
| Price | $9.73 | $6.03 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | ★ 110.8K | 22.3K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $105,646,000.00 | $27,769,304.00 |
| Revenue This Year | $62.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.51 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $5.23 | $4.28 |
| 52 Week High | $24.80 | $7.60 |
| Indicator | STRO | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 88.38 | 63.79 |
| Support Level | $7.88 | $4.72 |
| Resistance Level | $9.38 | $5.36 |
| Average True Range (ATR) | 0.63 | 0.34 |
| MACD | 0.73 | 0.18 |
| Stochastic Oscillator | 97.12 | 98.09 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.